Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a pharmaceutical company. It launched Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used topically to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. Its mechanism of action targets the M3 receptor in the sweat gland, blocking acetylcholine to reduce sweat at its source. Its segments include Australia and United States which generates all of the revenue.
Contact
2390 E Camelback Road
Suite 202
PhoenixAZ85016
USAT: +1 866 763-6337
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
1
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,112.46 | 47.44 | 0.59% |
| DAX 40 | 25,472.81 | 168.75 | 0.67% |
| Dow JONES (US) | 51,682.64 | 95.40 | -0.18% |
| FTSE 100 | 10,704.78 | 45.65 | 0.43% |
| HKSE | 24,995.34 | 244.56 | 0.99% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,650.50 | 12.74 | 0.17% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |